Expensify Inc vs Heron Therapeutics Inc — how do they compare? Expensify Inc trades at $2.27 (market cap $209.73M), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Expensify Inc is far larger — about 3.4× Heron Therapeutics Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | HRTX | |
|---|---|---|
Market Cap | $209.73M | $61.47M |
Sector | Technology | Health |
52-Week High | $2.69 | $1.49 |
52-Week Low | $0.75 | $0.32 |
Enterprise Value | $149.35M | $168.21M |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.4, down 2.83% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. However, it remains unprofitable on a net income basis, with a negative margin of -11.31% and a high P/E ratio of 258.82, indicating a premium valuation despite losses. Recent news highlights expansion into Europe and AI product enhancements.
The outlook is mixed; operational improvements and AI-driven growth offer upside, but persistent losses and high valuation pose risks. Analyst sentiment is balanced with a 44% buy rating. Investors should weigh the potential for margin expansion against the challenge of achieving sustained profitability.
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Trailing returns across standard periods
Latest headlines on both assets
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →